Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Díaz-González Á, Mora E, Avetisyan G, Furió S, De la Puerta R, Gil JV, Liquori A, Villamón E, García-Hernández C, Santiago M, García-Ruiz C, Llop M, Ferrer-Lores B, Barragán E, García-Palomares S, Mayordomo E, Luna I, Vicente A, Cordón L, Senent L, Álvarez-Larrán A, Cervera J, De la Rubia J, Hernández-Boluda JC, Such E. Díaz-González Á, et al. Among authors: garcia hernandez c. Cancers (Basel). 2023 Jun 2;15(11):3039. doi: 10.3390/cancers15113039. Cancers (Basel). 2023. PMID: 37297002 Free PMC article.
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.
Ferrer-Marín F, Arroyo AB, Bellosillo B, Cuenca EJ, Zamora L, Hernández-Rivas JM, Hernández-Boluda JC, Fernandez-Rodriguez C, Luño E, García Hernandez C, Kerguelen A, Fiallo-Suárez DV, Gómez-Casares MT, Ayala R, Vélez P, Boqué C, García-Gutierrez V, Arrizabalaga B, Estrada N, Cifuentes R, Arcas I, de Los Reyes-García AM, Besses C, Vicente V, Alvarez-Larrán A, Teruel-Montoya R, González-Conejero R, Martínez C; GEMFIN Group. Ferrer-Marín F, et al. Leukemia. 2020 Oct;34(10):2648-2659. doi: 10.1038/s41375-020-0767-3. Epub 2020 Feb 27. Leukemia. 2020. PMID: 32107471
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea.
Alvarez-Larrán A, Díaz-González A, Such E, Mora E, Andrade-Campos M, García-Hernández C, Gómez-Casares MT, García-Gutiérrez V, Carreño-Tarragona G, Garrote M, Fernández-Ibarrondo L, Cervera J, Bellosillo B, Cervantes F, Hernández-Boluda JC; MPN Spanish Group (GEMFIN). Alvarez-Larrán A, et al. Leukemia. 2021 Feb;35(2):623-627. doi: 10.1038/s41375-020-0849-2. Epub 2020 May 5. Leukemia. 2021. PMID: 32372025 Free PMC article. No abstract available.
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, Giraldo P, Angona A, Alvarez-Larrán A, Sanchez-Guijo F, Ramírez MJ, Mora E, Vélez P, Rosell A, Colorado Araujo M, Cuevas B, Sagüés M, Cortes M, Encinas MP, Casado Montero LF, Moreno Vega M, Serrano L, Gomez V, Garcia-Hernandez C, Lakhwani S, Paz Coll A, de Paz R, Suarez-Varela S, Fernandez-Ruiz A, Perez Lopez R, Ortiz-Fernández A, Jiménez-Velasco A, Steegmann-Olmedillas JL, Hernández-Boluda JC. Garcia-Gutiérrez V, et al. Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8. Blood Cancer J. 2021. PMID: 33563899 Free PMC article. No abstract available.
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V, Gasior M, Cuevas B, Angona A, Gómez-Casares MT, Martínez CM, Magro E, Ayala R, Del Orbe-Barreto R, Pérez-López R, Fox ML, Raya JM, Guerrero L, García-Hernández C, Caballero G, Murillo I, Xicoy B, Ramírez MJ, Carreño-Tarragona G, Hernández-Boluda JC, Pereira A; MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas). Alvarez-Larrán A, et al. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13. Cancer. 2022. PMID: 35417564 Free PMC article.
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Hernández-Boluda JC, Pastor-Galán I, Arellano-Rodrigo E, Raya JM, Pérez-Encinas M, Ayala R, Ferrer-Marín F, Velez P, Mora E, Fox ML, Hernández-Rivas JM, Xicoy B, Mata-Vázquez MI, García-Fortes M, Pérez-López R, Angona A, Cuevas B, Senín A, Ramírez MJ, Ramírez-Payer A, Gómez-Casares MT, Martínez-Valverde C, Magro E, Steegmann JL, Durán MA, García-Hernández C, Gasior M, de Villambrosia SG, Alvarez-Larrán A, Pereira A; Spanish MPN Group (GEMFIN). Hernández-Boluda JC, et al. Br J Haematol. 2022 Nov;199(4):529-538. doi: 10.1111/bjh.18440. Epub 2022 Sep 12. Br J Haematol. 2022. PMID: 36089912
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
Mosquera-Orgueira A, Pérez-Encinas M, Hernández-Sánchez A, González-Martínez T, Arellano-Rodrigo E, Martínez-Elicegui J, Villaverde-Ramiro Á, Raya JM, Ayala R, Ferrer-Marín F, Fox ML, Velez P, Mora E, Xicoy B, Mata-Vázquez MI, García-Fortes M, Angona A, Cuevas B, Senín MA, Ramírez-Payer A, Ramírez MJ, Pérez-López R, González de Villambrosía S, Martínez-Valverde C, Gómez-Casares MT, García-Hernández C, Gasior M, Bellosillo B, Steegmann JL, Álvarez-Larrán A, Hernández-Rivas JM, Hernández-Boluda JC. Mosquera-Orgueira A, et al. Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. eCollection 2023 Jan. Hemasphere. 2022. PMID: 36570691 Free PMC article.
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.
Santaliestra M, Garrote M, Noya MS, Pérez-Encinas M, Senín A, Pérez-López R, Ferrer-Marín F, Carreño-Tarragona G, Caballero G, Magro E, Vélez P, Cortés Vázquez MÁ, Moretó A, Angona A, Pastor-Galán I, Guerra JM, García Hernández C, Mata MI, Stuckey R, Gómez-Casares MT, Fox L, Cuevas B, García-Gutiérrez V, Triguero A, Arellano-Rodrigo E, Hernández-Boluda JC, Alvarez-Larrán A. Santaliestra M, et al. Among authors: garcia hernandez c. Leukemia. 2024 Sep 27. doi: 10.1038/s41375-024-02416-2. Online ahead of print. Leukemia. 2024. PMID: 39333760
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.
Alvarez-Larrán A, Angona A, Andrade-Campos M, Soledad Noya M, Teresa Gómez-Casares M, Cuevas B, Caballero G, García-Hernández C, García-Gutiérrez V, Palomino A, Ferrer-Marín F, Isabel Mata-Vázquez M, Moretó A, Magro E, Murillo I, Manuel Alonso-Domínguez J, María Guerra J, Guerrero L, María Raya J, Pérez-Encinas M, Carreño-Tarragona G, Fox L, Pastor-Galán I, Bellosillo B, Hernández-Boluda JC; MPN Spanish Group (GEMFIN). Alvarez-Larrán A, et al. Br J Haematol. 2021 Mar;192(6):988-996. doi: 10.1111/bjh.16988. Epub 2020 Aug 3. Br J Haematol. 2021. PMID: 32745264 Free article. Clinical Trial.
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, Vega MM, Alvarez-Larrán A, Salamanca A, García-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Pérez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jiménez-Velasco A, Lakhwani S, Casado LF, Rosell A, Escola A, Fernández MJ, Garcia-Hernandez C, Cervero C, Mora E, Sagüés M, Suarez-Varela S, Vélez P, Carrascosa Mastell P, Bitaube RF, Serrano L, Cortes M, Vera Goñi JA, Steegmann JL, de Soria VGG, Alonso-Dominguez JM, Araujo MC, Coll AP, Hernandez-Boluda JC, García-Gutiérrez V. Luna A, et al. Ann Hematol. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. Epub 2022 Aug 23. Ann Hematol. 2022. PMID: 35997804 Free PMC article.
76 results